The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Adverse Events Associated with Testosterone Administration
Open accessAbstract
BACKGROUND: Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied. METHODS: Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety monitoring board recommended that the trial be discontinued early because there was a significantly higher rate of adverse cardiovascular events in the testosterone group than in the placebo group. RESULTS: A total of 209 men (mean age, 74 years) were enrolled at the time the trial was terminated. At baseline, there was a high prevalence of hypertension, diabetes, hyperlipidemia, and obesity among the participants. During the course of the study, the testosterone group had higher rates of cardiac, respiratory, and dermatologic events than did the placebo group. A total of 23 subjects in the testosterone group, as compared with 5 in the placebo group, had cardiovascular-related adverse events. The relative risk of a cardiovascular-related adverse event remained constant throughout the 6-month treatment period. As compared with the placebo group, the testosterone group had significantly greater improvements in leg-press and chest-press strength and in stair climbing while carrying a load. CONCLUSIONS: In this population of older men with limitations in mobility and a high prevalence of chronic disease, the application of a testosterone gel was associated with an increased risk of cardiovascular adverse events. The small size of the trial and the unique population prevent broader inferences from being made about the safety of testosterone therapy. (ClinicalTrials.gov number, NCT00240981.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current evidence consistently shows that untreated low testosterone levels are associated with an increased risk of MACE”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, T supplementation is not without risk and could potentially be harmful concerning cardiovascular risk in the elderly [248].”
From Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology (2022) · cites this paper as [248]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have previously reported that testosterone levels are linked to a variety of conditions and diseases, such as cardiovascular disease, type-2 diabetes, the metabolic syndrome, erectile dysfunction, depression, obesity, stroke and osteoporosis. 1-7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“studies that measure cardiovascular benefit or harm in men on testosterone therapy have returned inconsistent and controversial results.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“the current scientific literature does not definitively demonstrate that testosterone therapy increases the risk of MACE.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“and that testosterone administration can increase the risk of cardiovascular adverse events as well. 7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
In the citing paper
“Low vitamin D levels have been associated with frailty (133)”
From Frailty in elderly people (2013) · cites this paper as [133]
In the citing paper
“Additionally, testosterone replacement is not without potential risks, including increased respiratory disorders (eg, cough, shortness of breath, asthma or chronic obstructive pulmonary disease (COPD) exacerbation, sleep apnoea) and skin and subcutaneous tissue disorders (eg, application site reactions, itching, erythema, foot ulcers, and increased hair growth).84”
From Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases (2014) · cites this paper as [84]
In the citing paper
“preventing an age-related decline in hormones by exogenous replacement is associated with increased risk for adverse effects in older adults.11-13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Unfortunately, hormone replacement therapy is not a panacea, as it often results in various adverse events which outweigh its potential health benefits.”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Some of the risks associated with T therapy include exacerbation of prostate cancer, cardiovascular-related events, hepatotoxicity, erythrocytosis, sleep apnea, and dermatological issues.12, 13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Serum hepcidin was measured by enzyme-linked immunosorbent assay (Intrinsic Life Sciences) with sensitivity of 5 ng/mL, interassay coefficient of variation 12%, and range 29-254 ng/ mL in men (12,15).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We have reported that administration of supraphysiologic doses of testosterone in healthy men suppresses the iron regulatory peptide hepcidin while EPO levels remained unchanged after 20 weeks of treatment (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We also show that testosterone administration is associated with lower hepcidin levels in older men with mobility limitation and high burden of chronic diseases, confirming our previous observations in healthy younger and older men and demonstrating a similar magnitude of hepcidin suppression (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“Changes in fat mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but can marginally continue over years.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
In the citing paper
“It can be concluded that the effects of testosterone on muscle strength are demonstrable after 12–20 weeks and that depending on the achieved testosterone levels, the maximum effects are attained after 6 or 12 months.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
In the citing paper
“Another study using high doses of testosterone gel (starting dose 100 mg/day with possible up-titration to 150 mg/day) observed significant increases in leg press strength, chest press strength, and stair climbing power with a load within 6 months (16).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability
Guralnik, J. M., Ferrucci, L., Simonsick, E. M., Salive, M. E., & Wallace, R. B. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503023320902 · Cited by 4,083
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationFried, L. P. (1998) · JAMA · doi:10.1001/jama.279.8.585 · Cited by 1,107
Newman, A. B., Simonsick, E. M., Naydeck, B. L., Boudreau, R. M., Kritchevsky, S. B., Nevitt, M. C., Pahor, M., Satterfield, S., Brach, J. S., Studenski, S. A., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2018 · Cited by 934
Testosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R., Morley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., & Ross, C. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.6.3988 · Cited by 920
Associations of Subclinical Cardiovascular Disease With Frailty
Newman, A. B., Gottdiener, J. S., McBurnie, M. A., Hirsch, C. H., Kop, W. J., Tracy, R. P., Walston, J. D., & Fried, L. P. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.3.m158 · Cited by 813
Predictors of skeletal muscle mass in elderly men and women
Baumgartner, R. N., Waters, D. L., Gallagher, D., Morley, J. E., & Garry, P. J. (1999) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(98)00130-4 · Cited by 809
Low Serum Testosterone and Mortality in Older Men
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1792 · Cited by 798
Effects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1210/jc.82.6.1661 · DOI
Cited by
Sorted by citations
Items 201–300 of 1,000
Comparative Safety of Testosterone Dosage Forms
Layton, J. B., Meier, C. R., Sharpless, J. L., Stürmer, T., Jick, S. S., & Brookhart, M. A. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.1573 · Cited by 96
Sex differences in vascular aging in response to testosterone
Moreau, K. L., Babcock, M. C., & Hildreth, K. L. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00294-8 · Cited by 98
Hypogonadism in the HIV-infected man
Rochira, V., & Guaraldi, G. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.06.005 · Cited by 95
Yeap, B. B., Alfonso, H. S., Chubb, S. A. P., Hankey, G. J., Handelsman, D. J., Golledge, J., Almeida, O. P., Flicker, L. A., & Norman, P. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2664 · Cited by 94
Traish, A. M. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000086 · Cited by 95
Sex differences in vascular endothelial function and health in humans: impacts of exercise
GREEN, D. J., Hopkins, N. D., Jones, H., Thijssen, D. H. J., Eijsvogels, T. M. H., & Yeap, B. B. (2015) · Experimental Physiology · doi:10.1113/ep085367 · Cited by 94
Why does COVID‐19 kill more elderly men than women? Is there a role for testosterone?
Papadopoulos, V., Li, L., & Samplaski, M. K. (2020) · Andrology · doi:10.1111/andr.12868 · Cited by 94
Review: Testosterone and the metabolic syndrome
Muraleedharan, V., & Jones, T. H. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810390258 · Cited by 98
Pison, C. M., Cano, N., Chérion, C., Caron, F., Court‐Fortune, I., Antonini, M.-T., Gonzalez‐Bermejo, J., Meziane, L., Molano, L. C., Janssens, J.-P., et al. (2011) · Thorax · doi:10.1136/thx.2010.154922 · Cited by 99
A Horizon Scan of Global Conservation Issues for 2016
Sutherland, W. J., Broad, S., Caine, J., Clout, M. N., Dicks, L. V., Doran, H., Entwistle, A. C., Fleishman, E., GIBBONS, D. W., Keim, B., et al. (2015) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2015.11.007 · Cited by 92
Risks of testosterone replacement therapy in men
Ramasamy, R., Osterberg, E. C., & Bernie, A. (2014) · Indian Journal of Urology · doi:10.4103/0970-1591.124197 · Cited by 92
Sex hormones and sarcopenia in older persons
Maggio, M. G., Lauretani, F., & Ceda, G. P. (2012) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32835b6044 · Cited by 91
Frailty: Diagnosis and management
Morley, J. E. (2011) · The journal of nutrition health & aging · doi:10.1007/s12603-011-0338-4 · Cited by 92
Motta, F., Sica, A., & Selmi, C. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.576134 · Cited by 92
Reactive oxygen species: players in the cardiovascular effects of testosterone
Tostes, R. C., Carneiro, F. S., de Carvalho, M. H. C., & Reckelhoff, J. F. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00392.2014 · Cited by 90
Adverse effects of testosterone replacement therapy: an update on the evidence and controversy
Grech, A., Breck, J., & Heidelbaugh, J. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614548680 · Cited by 81
Diagnosis and treatment of hypogonadism in men
Bhasin, S., & Basaria, S. S. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.12.002 · Cited by 89
Self-citationDrug‐induced peripheral oedema: An aetiology‐based review
Largeau, B., Cracowski, J., Lengellé, C., Sautenet, B., & Jonville‐Béra, A. ‐. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14752 · Cited by 89
Male late-onset hypogonadism: pathogenesis, diagnosis and treatment
Huhtaniemi, I., & Forti, G. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2011.47 · Cited by 88
Androgens’ effects on cerebrovascular function in health and disease
Abi‐Ghanem, C., Robison, L. S., & Zuloaga, K. L. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00309-4 · Cited by 89
The vulnerable man: impact of testosterone deficiency on the uraemic phenotype
Carrero, J. J., & Stenvinkel, P. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs383 · Cited by 90
Testosterone deficiency in men with Type 2 diabetes: pathophysiology and treatment
Gianatti, E., & Grossmann, M. (2019) · Diabetic Medicine · doi:10.1111/dme.13977 · Cited by 86
Bhasin, S., Ellenberg, S. S., Storer, T. W., Basaria, S. S., Pahor, M., Stephens‐Shields, A. J., Cauley, J. A., Ensrud, K. E., Farrar, J. T., Cella, D. F., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30171-2 · Cited by 87
Self-citationA UK epidemic of testosterone prescribing, 2001–2010
Gan, E. H., Pattman, S., Pearce, S. H. S., & Quinton, R. (2013) · Clinical Endocrinology · doi:10.1111/cen.12178 · Cited by 86
Current pharmacotherapies for sarcopenia
Hardee, J. P., & Lynch, G. S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1622093 · Cited by 89
Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review
Dandona, P., Dhindsa, S., Ghanim, H., & Saad, F. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14206 · Cited by 90
Testosterone and cardiovascular disease in men
Morris, P., & Channer, K. S. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2012.21 · Cited by 86
Sharma, R., Oni, O. A., Gupta, K., Sharma, M., Sharma, R., Singh, V., Parashara, D., Surineni, K., Dawn, B., Chen, G., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004880 · Cited by 86
Clinically Meaningful Change for Physical Performance: Perspectives of the ICFSR Task Force
Guralnik, J. M., Bandeen‐Roche, K., Bhasin, S., Eremenco, S., Landi, F., Muscedere, J., Perera, S., Reginster, J., Woodhouse, L. J., & Vellas, B. J. (2020) · The Journal of Frailty & Aging · doi:10.14283/jfa.2019.33 · Cited by 85
Self-citationUsselman, C. W., Yarovinsky, T. O., Steele, F. E., Leone, C. A., Taylor, H. S., Bender, J. R., & Stachenfeld, N. S. (2019) · The Journal of Physiology · doi:10.1113/jp277756 · Cited by 86
Testosterone therapy increased muscle mass and lipid oxidation in aging men
Frederiksen, L., Højlund, K., HOUGAARD, D. M., Brixen, K., & Andersen, M. (2011) · AGE · doi:10.1007/s11357-011-9213-9 · Cited by 84
Human androgen deficiency: insights gained from androgen receptor knockout mouse models
Zajac, J. D., Rana, K., & Davey, R. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122590 · Cited by 91
Interactions between age, sex, and hormones in experimental ischemic stroke
Liu, F., & McCullough, L. D. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.10.003 · Cited by 86
Testosterone deficiency: A determinant of aortic stiffness in men
Vlachopoulos, C. V., Ioakeimidis, N., Miner, M. M., Aggelis, A., Pietri, P. G., Terentes-Printzios, D. G., Tsekoura, D., & Stefanadis, C. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.010 · Cited by 82
Illicit use of androgens and other hormones
Kanayama, G., & Pope, H. G. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283524008 · Cited by 84
Importance of sex and gender in ischaemic stroke and carotid atherosclerotic disease
Gasbarrino, K., Iorio, D. D., & Daskalopoulou, S. S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab756 · Cited by 84
Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction
Suda, M., Paul, K. H., Tripathi, U., Minamino, T., Tchkonia, T., & Kirkland, J. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae010 · Cited by 83
Off-label use of hormones as an antiaging strategy: a review
Samaras, N., Papadopoulou, M.-A., Samaras, D., & Ongaro, F. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s48918 · Cited by 83
Cellular interplay in skeletal muscle regeneration and wasting: insights from animal models
Henrot, P., Blervaque, L., Dupin, I., Zysman, M., Estèves, P., Gouzi, F., Hayot, M., Pomiès, P., & Berger, P. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13103 · Cited by 88
Cigarette smoking has a positive and independent effect on testosterone levels
Wang, W., Yang, X., Liang, J., Liao, M., Zhang, H., Qin, X., Mo, L., Lv, W., & Mo, Z. (2013) · Hormones · doi:10.14310/horm.2002.1445 · Cited by 79
The Endocrinology of Ageing: A Mini-Review
Jones, C. M., & Boelaert, K. (2014) · Gerontology · doi:10.1159/000367692 · Cited by 83
Wehr, E., Pilz, S., Boehm, B. O., März, W., Grammer, T., & Obermayer-Pietsch, B. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr007 · Cited by 78
Aging in blood vessels. Medicinal agents FOR systemic arterial hypertension in the elderly
Rubio-Ruiz, M. E., Pérez-Torres, I., Soto, M. E., Pastelı́n, G., & Guarner‐Lans, V. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.10.001 · Cited by 80
Injectable testosterone undecanoate for the treatment of hypogonadism
Corona, G., Maseroli, E., & Maggi, M. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.944896 · Cited by 79
Testosterone therapy, thrombosis, thrombophilia, cardiovascular events
Glueck, C. J., & Wang, P. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.005 · Cited by 79
Uncovering sex-specific mechanisms of action of testosterone and redox balance
Cruz‐Topete, D., Dominic, P. S., & Stokes, K. Y. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101490 · Cited by 77
Fui, M. N. T., Hoermann, R., Bracken, K., Handelsman, D. J., Inder, W. J., Stuckey, B. G. A., Yeap, B. B., Ghasemzadeh, A., Robledo, K. P., Jesudason, D. R., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab149 · Cited by 80
Muraleedharan, V., & Jones, T. H. (2014) · Clinical Endocrinology · doi:10.1111/cen.12503 · Cited by 78
Skinner, J. W., Otzel, D. M., Bowser, A., Nargi, D., Agarwal, S., Peterson, M. D., Zou, B., Borst, S. E., & Yarrow, J. F. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12291 · Cited by 76
Hoogeboom, T. J., Kousemaker, M. C., van Meeteren, N. L., Howe, T., Bo, K., Tugwell, P., Ferreira, M., de Bie, R. A., van den Ende, C. H., & Stevens-Lapsley, J. E. (2021) · British Journal of Sports Medicine · doi:10.1136/bjsports-2019-101630 · Cited by 76
Testosterone Therapy: What We Have Learned From Trials
Corona, G., Torres, L. O., & Maggi, M. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.11.270 · Cited by 78
Managing Sarcopenia and Its Related-Fractures to Improve Quality of Life in Geriatric Populations
Hida, T. (2014) · Aging and Disease · doi:10.14336/ad.2014.0500226 · Cited by 77
Randomized controlled trials – mechanistic studies of testosterone and the cardiovascular system
Jones, T. H., & Kelly, D. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_6_18 · Cited by 76
The practical management of testosterone deficiency in men
Aversa, A., & Morgentaler, A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.238 · Cited by 75
Yoshida, S., Aihara, K., Ikeda, Y., Sumitomo-Ueda, Y., Uemoto, R., Ishikawa, K., Ise, T., Yagi, S., Iwase, T., Mouri, Y., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001533 · Cited by 73
Erectile dysfunction, metabolic syndrome, and cardiovascular risks: facts and controversies
Sanchez, E., Pastuszak, A. W., & Khera, M. (2017) · Translational Andrology and Urology · doi:10.21037/tau.2016.10.01 · Cited by 73
Enobosarm (GTx-024, S-22): A Potential Treatment for Cachexia
Srinath, R., & Dobs, A. S. (2014) · Future Oncology · doi:10.2217/fon.13.273 · Cited by 75
Santoro, N. F., Braunstein, G. D., Butts, C. L., Martin, K. A., McDermott, M., & Pinkerton, J. V. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1271 · Cited by 75
Diem, S. J., Greer, N. L., MacDonald, R. H., McKenzie, L. G., Dahm, P., Ercan-Fang, N. G., Estrada, A., Hemmy, L. S., Rosebush, C. E., Fink, H. A., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-0830 · Cited by 72
Yu, I.-C. I., Lin, H., Sparks, J. D., Yeh, S., & Chang, C. (2014) · Diabetes · doi:10.2337/db13-1505 · Cited by 71
Shores, M. M., Arnold, A. M., Biggs, M. L., Longstreth, W. T., Smith, N. L., Kizer, J. R., Cappola, A. R., Hirsch, C. H., Marck, B. T., & Matsumoto, A. M. (2014) · Clinical Endocrinology · doi:10.1111/cen.12452 · Cited by 71
Goodman, N. F., Guay, A. T., Dandona, P., Dhindsa, S., Faiman, C., & Cunningham, G. R. (2015) · Endocrine Practice · doi:10.4158/ep14434.ps · Cited by 72
Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men
Kaufman, J. M., Miller, M. G., Garwin, J. L., Fitzpatrick, S., McWhirter, C., & Brennan, J. J. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02265.x · Cited by 70
Carson, C. C., & Rosano, G. M. C. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02337.x · Cited by 70
Optimizing Skeletal Muscle Anabolic Response to Resistance Training in Aging
Endo, Y., Nourmahnad, A., & Sinha, I. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00874 · Cited by 77
Management of side effects of androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.004 · Cited by 69
Update of the position paper on arterial hypertension and erectile dysfunction
Viigimaa, M., Vlachopoulos, C. V., Doumas, M. N., Wolf, J., Imprialos, K. P., Terentes-Printzios, D. G., Ioakeimidis, N., Kotsar, A., Kiitam, U., Stavropoulos, K., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002382 · Cited by 69
Increased Muscle Force Production and Bone Mineral Density in ActRIIB-Fc-Treated Mature Rodents
Chiu, C.-S., Peekhaus, N., Weber, H., Adamski, S., Murray, E. M., Zhang, H. Z., Zhao, J. Z., Ernst, R., Lineberger, J., Huang, L., et al. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt030 · Cited by 68
Effects of lifelong testosterone exposure on health and disease using Mendelian randomization
Mohammadi‐Shemirani, P., Chong, M., Pigeyre, M., Morton, R. W., Gerstein, H. C., & Paré, G. (2020) · eLife · doi:10.7554/elife.58914 · Cited by 70
Management of Osteoporosis in Men: A Narrative Review
Vescini, F., Chiodini, I., Falchetti, A., Palermo, A., Salcuni, A. S., Bonadonna, S., Geronimo, V. D., Cesareo, R., Giovanelli, L., Brigo, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413640 · Cited by 71
Association Between Testosterone Replacement Therapy and the Incidence of DVT and Pulmonary Embolism
Sharma, R., Oni, O. A., Chen, G., Sharma, M., Dawn, B., Sharma, R., Parashara, D., Savin, V. J., Barua, R. S., & Gupta, K. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.05.007 · Cited by 68
Effect of lifestyle intervention on the hormonal profile of frail, obese older men
Armamento-Villareal, R., Aguirre, L. E., Qualls, C., & Villareal, D. T. (2016) · The Journal of nutrition, health and aging · doi:10.1007/s12603-016-0698-x · Cited by 67
Gianatti, E. J., Dupuis, P., Hoermann, R., Zajac, J. D., & Grossmann, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1872 · Cited by 67
Sildenafil increases serum testosterone levels by a direct action on the testes
Spitzer, M., Bhasin, S., Travison, T. G., Davda, M. N., Stroh, H., & Basaria, S. (2013) · Andrology · doi:10.1111/j.2047-2927.2013.00131.x · Cited by 67
“for placebo groups from other clinical trials, which imposed similar ‘low testosterone’ criteria as a condition of enrolment (Sih et al., 1997; Snyder et al., 1999; Steidle et al., 2003; Basaria et al., 2010; Srinivas-Shankar et al., 2010).”
BackgroundMethodInfluentialSelf-citationSarcopenia and Frailty: Challenges in Mainstream Nephrology Practice
Wong, L., Duque, G., & McMahon, L. P. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.039 · Cited by 68
Sexual Dysfunction in Men with COPD: Impact on Quality of Life and Survival
Collins, E. G., Halabi, S., Langston, M., Schnell, T., Tobin, M. J., & Laghi, F. A. (2012) · Lung · doi:10.1007/s00408-012-9398-4 · Cited by 67
The role of sex steroid hormones in the pathophysiology and treatment of sarcopenia
Kim, Y. J., Tamadon, A., Park, H. T., Kim, H., & Ku, S. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.06.002 · Cited by 76
The Endocrine Role of Estrogens on Human Male Skeleton
Rochira, V., Kara, E., & Carani, C. (2015) · International Journal of Endocrinology · doi:10.1155/2015/165215 · Cited by 69
Critical evaluation of different available guidelines for late‐onset hypogonadism
Giagulli, V., Castellana, M., Lisco, G., & Triggiani, V. (2020) · Andrology · doi:10.1111/andr.12850 · Cited by 54
Senolytic treatment rescues blunted muscle hypertrophy in old mice
Dungan, C. M., Figueiredo, V. C., Wen, Y., VonLehmden, G. L., Zdunek, C. J., Thomas, N. T., Mobley, C. B., Murach, K. A., Brightwell, C. R., Long, D. E., et al. (2022) · GeroScience · doi:10.1007/s11357-022-00542-2 · Cited by 65
Jaitovich, A., Dumas, C. L., Itty, R., Chieng, H., Khan, M. M. H. S., Naqvi, A. R., Fantauzzi, J. P., Hall, J. B., Feustel, P. J., & Judson, M. A. (2020) · Critical Care · doi:10.1186/s13054-020-03276-9 · Cited by 65
Pharmacoepidemiology of testosterone prescribing in Australia, 1992–2010
Handelsman, D. J. (2012) · The Medical Journal of Australia · doi:10.5694/mja11.11277 · Cited by 65
Morgentaler, A., Traish, A. M., Hackett, G. I., Jones, T. H., & Ramasamy, R. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2019.06.003 · Cited by 67
Testosterone and metabolic syndrome
Cunningham, G. R. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.148068 · Cited by 65
Association of Testosterone Levels With Endothelial Function in Men
Empen, K., Lorbeer, R., Dörr, M., Haring, R., Nauck, M. A., Gläser, S., Krebs, A., Reffelmann, T., Ewert, R., Völzke, H., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.232876 · Cited by 64
Babcock, M. C., DuBose, L. E., Witten, T. L., Stauffer, B. L., Hildreth, K. L., Schwartz, R. S., Kohrt, W. M., & Moreau, K. L. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab715 · Cited by 64
Borst, S. E., & Yarrow, J. F. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00111.2015 · Cited by 63
Rehabilitation and acute exacerbations
Burtin, C., Decramer, M., Gosselink, R., Janssens, W., & Troosters, T. (2011) · European Respiratory Journal · doi:10.1183/09031936.00079111 · Cited by 64
Exterkate, L., Slegtenhorst, B. R., Kelm, M., Seyda, M., Schuitenmaker, J. M., Quante, M., Uehara, H., Elkhal, A., & Tullius, S. G. (2015) · Transplantation · doi:10.1097/tp.0000000000001003 · Cited by 64
Magnussen, L. V., Glintborg, D., Hermann, A. P., HOUGAARD, D. M., Højlund, K., & Andersen, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12701 · Cited by 64
Hematological changes during androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.102 · Cited by 62
Schwartz, L. M., & Woloshin, S. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.7579 · Cited by 62
Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy
Pan, Y., Davis, P. B., Kaebler, D. C., Blankfield, R. P., & Xu, R. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01610-9 · Cited by 64
Critical Update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism
Seftel, A. D., Kathrins, M. N., & Niederberger, C. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.002 · Cited by 63
Chiang, J. M., Kaysen, G. A., Segal, M. R., Chertow, G. M., Delgado, C., & Johansen, K. L. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy252 · Cited by 62
Role of androgens in cardiovascular pathology
Chistiakov, D. A., Myasoedova, V. A., Melnichenko, A. А., Grechko, A. V., & Orekhov, A. N. (2018) · Vascular Health and Risk Management · doi:10.2147/vhrm.s173259 · Cited by 65
Yeap, B. B., Grossmann, M., McLachlan, R. I., Handelsman, D. J., Wittert, G. A., Conway, A. J., Stuckey, B. G., Lording, D. W., Allan, C. A., Zajac, J. D., et al. (2016) · Medical Journal of Australia · doi:10.5694/mja16.00448 · Cited by 61
Screening and Monitoring in Men Prescribed Testosterone Therapy in the U.S., 2001–2010
Baillargeon, J., Urban, R. J., Kuo, Y.-F., Holmes, H. M., Raji, M. A., Morgentaler, A., Howrey, B. T., Lin, Y.-L., & Ottenbacher, K. J. (2015) · Public Health Reports® · doi:10.1177/003335491513000207 · Cited by 61
Death by Testosterone? We Think Not!
Traish, A. M., Guay, A. T., & Morgentaler, A. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12464 · Cited by 61
Testosterone Treatment and Cardiovascular and Venous Thromboembolism Risk: What is ‘New’?
Corona, G., Dicuio, M., Rastrelli, G., Maseroli, E., Lotti, F., Sforza, A., & Maggi, M. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000411 · Cited by 61
Metadata
- Authors
- Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., Choong, K., Lakshman, K. M., Mazer, N. A., Miciek, R., Krasnoff, J., Elmi, A., Knapp, P. E., Brooks, B., Appleman, E., Aggarwal, S., Bhasin, G., Hede-Brierley, L., Bhatia, A., Collins, L., LeBrasseur, N., Fiore, L. D., & Bhasin, S.
- Affiliations
- Boston University (US)
- Brigham and Women's Hospital (US)
- New England Research Institutes (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-08
- Volume
- 363
- Issue
- 2
- Pages
- 109-122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3440621
- OpenAlex
- W2155877918
- Cited by
- 1,494
- References
- 56
- Citations by year
- 2026: 33 · 2025: 52 · 2024: 68 · 2023: 63 · 2022: 76 · 2021: 66 · 2020: 91 · 2019: 65 · 2018: 92 · 2017: 132 · 2016: 103 · 2015: 122 · 2014: 169 · 2013: 96 · 2012: 108
- FWCI
- 85.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5p30ag031679-15)
- National Institute on Aging (U01AG014369, R01AG037193, 5 P30 AG031679, P30-AG031679, 1UO1AG14369)
- National Center for Research Resources (UL1RR025771)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- testosterone replacement therapy, testosterone gel, adverse events, cardiovascular events, older men, mobility limitations, hypogonadism, muscle strength, trial discontinuation, drug safety
- MeSH terms
- Administration, Cutaneous, Aged, Aged, 80 and over, Cardiovascular Diseases, Double-Blind Method, Exercise Test, Gels, Humans, Hyperlipidemias, Hypertension, Male, Obesity, Risk Factors, Testosterone, Logistic Models, Walking, Kaplan-Meier Estimate, Muscle Strength
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
